A practical reference on angiotensin IV: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
Indeed, evaluating such predictions often requires a structural alignment between the model and the true known structure to assess the model's quality. Structural alignments are especially useful in analyzing data from structural genomics and proteomics efforts, and they can be used as comparison points to evaluate alignments produced by purely sequence-based bioinformatics methods. The outputs of a structural alignment are a superposition of the atomic coordinate sets and a minimal root mean square deviation (RMSD) between the structures. The RMSD of two aligned structures indicates their divergence from one another. Structural alignment can be complicated by the existence of multiple protein domains within one or more of the input structures, because changes in relative orientation of the domains between two structures to be aligned can artificially inflate the RMSD.
The Gulf War began with an extensive aerial bombing campaign on 16 January 1991. For 42 consecutive days and nights, the coalition forces subjected Iraq to one of the most intensive air bombardments in military history. The coalition flew over 100,000 sorties, dropping 88,500 tonnes of bombs, which widely destroyed military and civilian infrastructure. Iraqi anti-aircraft defenses, including man-portable air-defense systems, were surprisingly ineffective against enemy aircraft, and the coalition suffered only 75 aircraft losses in over 100,000 sorties, 44 due to Iraqi action. Two of these losses are the result of aircraft colliding with the ground while evading Iraqi ground-fired weapons. One of these losses is a confirmed air-air victory.
Unlabeled antibody is incubated in the presence of its antigen (sample) A sufficient incubation period is provided to allow the antibodies to bind to the antigens. The sample is then passed through the Scavenger container. This can be a test tube or a specifically designed flow through channel. The surface of the Scavenger container or channel has "Scavenger Antigens" bound to it. These can be identical or sufficiently similar to the primary antigens that the free antibodies will bind. The Scavenger container must have sufficient surface area and sufficient time to allow the Scavenger Antigens to bind to all the excess Antibodies introduced into the sample. The sample, that now contains the tagged and bound antibodies, is passed through a detector. This device can be a flow cytometer or other device that illuminates the tags and registers the response. This test allows multiple antigens to be tagged and counted at the same time. This allows specific strains of bacteria to be identified by two (or more) different color tags. If both tags are present on a cell, then the cell is that specific strain. If only one is present, it is not. This test is done, generally, one test at a time and cannot be done with the microtiter plate. The equipment needed is usually less complicated and can be used in the field.
Modafinil sulfone (code name CRL-41056) is an achiral, oxidized metabolite of modafinil, a wakefulness-promoting agent. It is one of two major circulating metabolites of modafinil, the other being modafinil acid. Modafinil sulfone is also a metabolite of the modafinil prodrug, adrafinil. Modafinil sulfone is also a metabolite of armodafinil, the (R)-(–)-enantiomer of modafinil, as oxidation to the sulfone removes the chiral center at the sulfur atom. Modafinil sulfone has been described as inactive, and similarly to modafinil acid, does not appear to contribute to the wakefulness-promoting effects of modafinil. However, like modafinil, modafinil sulfone was found to show anticonvulsant properties in animals, indicating that it does possess some biological activity.
Sources: en.wikipedia.org
=== Biological battery === A “biological battery” was demonstrated in late 2025 at Belmonte Arboretum, part of Wageningen University & Research as part of its program provides educational scientific experiences to young people. In this case a path was marked by small Light-emitting diodes (LEDs) that provide a diffuse night-time glow sufficient to mark the path without disturbing nature. The electricity used to power the LEDs is essentially sunlight that fell on green photosynthesising living plant material. That process takes water from the ground (H2O) and carbon dioxide (CO2) in the air to rearrange the hydrogen and oxygen into carbohydrate molecules, releasing unwanted oxygen to the air. Only some of the solar energy collected by the green material is used for photosynthesis, some is discharged through the roots into the soil, where bacteria use it to synthesize other essential molecules and elements such as nitrogen that support plant life. To extract electricity from sunlight, conductive carbon electrodes were introduced near the roots of bushes to capture the “free” electrons produced by bacteria. These serve as the negative cell terminals, other carbon electrodes placed in the air provided the corresponding positive connections. Although the energy captured from a single bush is very small many can be connected in series (a “battery” of "cells") to provide enough to drive the LEDs without conventional electrochemical cells or regular solar cells.
== Regulation == NADK is highly regulated by the redox state of the cell. Whereas NAD is predominantly found in its oxidized state NAD+, the phosphorylated NADP is largely present in its reduced form, as NADPH. Thus, NADK can modulate responses to oxidative stress by controlling NADP synthesis. Bacterial NADK is shown to be inhibited allosterically by both NADPH and NADH. NADK is also reportedly stimulated by calcium/calmodulin binding in certain cell types, such as neutrophils. NAD kinases in plants and sea urchin eggs have also been found to bind calmodulin.
Inmates on Oklahoma's death row alleged that the use of midazolam was unconstitutional because the drug was not proven to render a person unconscious as thiobarbital would. The Supreme Court found that the prisoners failed to demonstrate that midazolam would create a high risk of severe pain and that the prisoners had not provided an alternative, practical method of execution that would have a lower risk. Consequently, it ruled that the new method was permissible under the Eighth Amendment. On March 15, 2018, Russell Bucklew, a Missouri death-row inmate who had been scheduled to be executed on May 21, 2014, appealed the constitutionality of lethal injection on an as-applied basis. The basis for Bucklew's appeal was due to Bucklew's allegation that his rare medical condition would interfere with the effects of the drugs, potentially causing him to choke on his blood. On April 1, 2019, The Supreme Court ruled against Bucklew on the grounds that his proposed alternative to lethal injection, nitrogen hypoxia, was neither "readily implemented" nor established to "significantly reduce a substantial risk of severe pain." Bucklew was executed on October 1, 2019.
Sources: en.wikipedia.org
Later, in 1687 in the Philosophiæ Naturalis Principia Mathematica, Newton showed mathematically that in an elastic fluid consisting of particles at rest, between which are repulsive forces inversely proportional to their distance, the density would be directly proportional to the pressure, but this mathematical treatise does not involve any Mariott temperature dependence and is not the proper physical explanation for the observed relationship. Instead of a static theory, a kinetic theory is needed, which was developed over the next two centuries by Daniel Bernoulli (1738) and more fully by Rudolf Clausius (1857), Maxwell and Boltzmann. This law was the first physical law to be expressed in the form of an equation describing the dependence of two variable quantities.
==== Hard disk ==== The use of hard disk storage has increased over time as it has become progressively cheaper. Hard disks are usually easy to use, widely available, and can be accessed quickly. However, hard disk backups are close-tolerance mechanical devices and may be more easily damaged than tapes, especially while being transported. In the mid-2000s, several drive manufacturers began to produce portable drives employing ramp loading and accelerometer technology (sometimes termed a "shock sensor"), and by 2010 the industry average in drop tests for drives with that technology showed drives remaining intact and working after a 36-inch non-operating drop onto industrial carpeting. Some manufacturers also offer 'ruggedized' portable hard drives, which include a shock-absorbing case around the hard disk, and claim a range of higher drop specifications. Over a period of years the stability of hard disk backups is shorter than that of tape backups. External hard disks can be connected via local interfaces like SCSI, USB, FireWire, or eSATA, or via longer-distance technologies like Ethernet, iSCSI, or Fibre Channel. Some disk-based backup systems, via Virtual Tape Libraries or otherwise, support data deduplication, which can reduce the amount of disk storage capacity consumed by daily and weekly backup data.
Luria–Nebraska Neuropsychological Battery A standardized test battery used to assess a wide range of cognitive and motor functions. Based on the work of Alexander Luria, it helps localize brain dysfunction.
=== Federal politics (2011–2025) === She was named the Conservative Party's candidate for Delta—Richmond East in March 2011, and won the seat in that year's federal election. During the 41st Parliament, she served as member of the House of Commons Standing Committee on Justice and Human Rights, and sat on a selection panel to help choose a replacement for Marie Deschamps of Quebec, who retired as puisne justice of the Supreme Court of Canada. She was named Parliamentary Secretary to the Minister of Justice in May 2011, and as Associate Minister of National Defence on February 22, 2013. She then served as the Minister of National Revenue from July 15, 2013, until November 4, 2015.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.